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Abstract
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by progressive neuronal
loss and degeneration of upper motor neuron (UMN) and lower motor neuron (LMN). The clinical presentations of ALS
are heterogeneous and there is no single test or procedure to establish the diagnosis of ALS. Most cases are diagnosed
based on symptoms, physical signs, progression, EMG, and tests to exclude the overlapping conditions. Familial ALS
represents about 5 ~ 10 % of ALS cases, whereas the vast majority of patients are sporadic. To date, more than 20
causative genes have been identified in hereditary ALS. Detecting the pathogenic mutations or risk variants for each
ALS individual is challenging. However, ALS patients carrying some specific mutations or variant may exhibit subtly
distinct clinical features. Unraveling the respective genotype-phenotype correlation has important implications for the
genetic explanations. In this review, we will delineate the clinical features of ALS, outline the major ALS-related genes,
and summarize the possible genotype-phenotype correlations of ALS.
Keywords: Amyotrophic lateral sclerosis, Diagnosis of ALS, Causative genes, Genetic explanations, Genotype-
phenotype correlations
Background
Amyotrophic lateral sclerosis (ALS) is a devastating and
inexorable neurodegenerative disease characterized by
progressive neuronal loss and degeneration of upper
motor neuron (UMN) and lower motor neuron (LMN)
[1]. It is the most widespread type of motor neuron dis-
ease and has become the third most common neurode-
generative disease in the world [2]. Patients affected with
ALS typically suffer from progressive muscle weakness
and atrophy and usually die from respiratory failure 2 to
3 years after the onset [3]. ALS is a relentless and incur-
able disease. There has been no effective therapeutic ap-
proach to halt the progression so far. ALS is
heterogeneous in its presentation, course, and progres-
sion. No single test for diagnosing ALS exists; most
cases are diagnosed based on symptoms, physical signs,
progression, EMG, and tests to exclude the overlapping
conditions.
The etiology of ALS is not fully understood. Appropri-
ate 5 ~ 10 % of ALS is familial (FALS) with a Mendelian
pattern of inheritance, suggesting that genetic factors
play important roles in the pathogenesis of ALS [4]. To
date, more than 20 causative genes have been identified
in hereditary ALS. In addition, about 30 potential causa-
tive or disease-modifying genes have also been identified.
Detecting the pathogenic mutations or risk variants for
each ALS individual is therefore challenging. Clinical
features do not reliably separate the hereditary ALS from
sporadic ALS (SALS) due to phenotypic overlap. How-
ever, ALS patients carrying some specific mutations may
exhibit subtly distinct clinical features. Unraveling the
genotype-phenotype correlations has important implica-
tions for the genetic explanations. In this review, we will
delineate the clinical features of ALS, outline the major
ALS-related genes, and review the possible genotype-
phenotype correlations. We hope this review will be in
favor of improving the accuracy of genetic screenings.
Clinical features of ALS
ALS usually commences in later life, with a mean age at
onset (AAO) of 65 year. The onset for FALS tends to be
earlier than that of SALS. A small proportion of patients
may developed juvenile ALS (JALS), in which onset oc-
curs in the first two decades [5]. Symptoms usually begin
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in the limbs (termed limb onset), although approximate
25 % of ALS patients have bulbar onset. Associated with
poorer prognosis, bulbar onset is more common in eld-
erly patients and women [6]. Upper limb weakness and
atrophy at onset are most common, subsequently
spreading to involve bulbar, trunk, or respiratory muscle
[7]. After initial presentation of symptoms, the disease
progresses to include both UMN and LMN symptoms
and signs. The UMN disturbance involving limbs leads
to spasticity, weakness, and brisk reflexes. The LMN fea-
tures of limbs comprise muscle atrophy, weakness, fasci-
culation, and decreased reflexes. As limb function
deteriorates, patients gradually lose their ability to walk.
Bulbar UMN dysfunction includes spastic dysarthria and
brisk jerk of gag and jaw, while bulbar LMN dysfunction
includes tongue wasting, weakness, and fasciculation. In
the later stage of ALS, most cases develop dysphagia,
which are associated with weight loss and malnutrition.
Sensory loss is usually absent, but cognitive impair-
ment is common in ALS cases. A significant proportion
of ALS cases develop cognitive dysfunction, and in a mi-
nority, overt dementia [7]. With appropriate cognitive
assessment, 20 ~ 50 % of patients with ALS fulfill the
consensus criteria for probable or definite frontal tem-
poral dementia (FTD) [8]. In addition, about 30 % of
FTD patients manifest signs of motor system dysfunc-
tion [9]. The occurrence of ALS, FTD, or ALS with FTD
in intra-familial members discloses a considerable over-
lap between ALS and FTD.
Causative genes
Since the identification of first causative gene in 1993, a
growing number of ALS-causing genes associated with
Mendelian inheritance have been identified. Although
FALS represents only 5 ~ 10 % of ALS cases, investiga-
tions of the causative genes have greatly increased our
understanding of the etiology of ALS. FALS is generally
inherited in an autosomal dominant pattern and rarely
inherited as an autosomal recessive or X-linked trait
[10]. Adult onset autosomal dominant inheritance is
more common than juvenile onset which is usually
caused by recessive transmission.
To date, at least 21 chromosomal regions containing
19 identified genes have been linked to ALS, termed as
ALS 1–21 respectively (Table 1). In 2011, the chromo-
some 9 open reading frame 72 (C9ORF72) repeat expan-
sions were identified in a significant proportion of ALS
and FTD patients, becoming the most common genetic
cause of ALS in the Caucasian population. There has
been strong evidence to support the pathogenic role for
mutations in Cu/Zn superoxide dismutase 1 (SOD1),
Fused in sarcoma (FUS), TAR DNA-binding protein
(TARDBP), and C9ORF72. However, mutations in other
genes are not common or even rarely seen in ALS cases.
In addition to the aforementioned ALS genes, a constel-
lation of other genes have also been implicated in ALS
[11]. But mutations in these genes are only identified in
a small fraction of ALS patients, indicating that these




The first causative gene of ALS was identified as SOD1
in 1993 [12]. Mutations in SOD1 are very common, ac-
counting for about 20 % of FALS and 1 ~ 2 % SALS
cases [13]. To date, more than 185 disease-associated
mutations have been described, spread throughout all
the 5 exons of SOD1 [14]. The majority of SOD1 muta-
tions are missense mutations, while small deletions or
insertions are also described [15]. The pattern of inherit-
ance is autosomal dominant except for the p.D90A mu-
tation which is recessive in the Scandinavian population
and dominant in others [16]. Among the SOD1 muta-
tions, p.D90A is the most common worldwide. However,
regional disparity of SOD1 mutations also exists. For ex-
ample, the most frequent SOD1 mutation in North
America is p.A4V [17], but in the UK and Japan, the
most common mutations are p.I113T, and p.H46R, re-
spectively [18].
Overall, most patients with SOD1 mutations develop a
rapidly progressive ALS, although some cases show a di-
verse phenotype. AAO and severity may vary signifi-
cantly depending on the variants involved. Patients with
p.A4V, p.H43R, p.L84V, p.G85R, p.N86S, or p.G93A mu-
tations exhibit an aggressive form of ALS with survival
shorter than 3 years, while cases with p.G93C, p.D90A,
or p.H46R mutations show longer life expectancies [18].
Cognitive impairment is very rare and bulbar onset is
less frequent than in other FALS types [19]. Some cases
with SOD1 mutations have distinct clinical features. Pa-
tients carrying homozygous p.D90A mutation manifest
insidious onset and a slow progression of ALS, with
bladder involvement at the later stage [20]. In contrast,
heterozygous p.D90A mutation is associated with vari-
ous forms of ALS, including bulbar onset, upper-limb
onset and fast progression, and lower-limb onset with
fast progression [21, 22]. The p.A4V mutation causes a
limb-onset aggressive form of ALS, with survival less
than 2 years after the onset [23]. Cases with p.A4T mu-
tation have a similar phenotype to that seen in p.A4V
mutation [24]. We previously reported SOD1 p.C111Y
and p.G147D mutations in 3 Chinese ALS families. The
p.C111Y mutation led to a relatively mild ALS pheno-
type, while the p.G147D was associated with a rapid pro-
gressive ALS [25]. The recently reported novel p.R115C
mutation was identified in an ALS patient who had an
extremely rapid progression and aggressive phenotype
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Table 1 Different subtypes of familial ALS and their genotype–phenotype correlations
ALS type Gene Inheritance ALS features FTD Other features/disorders
(chromosome)
ALS 1 SOD1 AD; AR; AAO: adult > juvenile; Onset: LL > UL > bulbar; Rare PMA, PBP, BFA, cerebellar ataxia, autonomic
dysfunction
(21q22.1) De novo Progression: rapid > slow; UMN + LMN > LMN
dominant
ALS 2 ALSIN AR AAO: juvenile; Onset: LL, UL; None PLS, IAHSP
(2q33.2) Progression: slow; UMN dominant > UMN + LMN
ALS 3 UN AD N/A N/A N/A
(18q21)
ALS 4 SETX AD AAO: juvenile > adult; Onset: LL > UL; None AOA2, cerebellar ataxia, motor neuropathy
(9q34) Progression: slow; UMN + LMN > LMN dominant
ALS 5 SPG11 AR AAO: juvenile > adult; Onset: bulbar, limb; Rare HSP, autonomic dysfunction, mental retardation
(15q21.1) Progression: slow; UMN dominant > UMN + LMN
ALS 6 FUS AD; AR; AAO: adult > juvenile; Onset: UL, bulbar > LL; Rare PMA, Parkinsonism, essential tremor, mental
retardation
(16q11.2) De novo Progression: rapid > slow; UMN + LMN > LMN
dominant
ALS 7 UN AD N/A N/A N/A
(20p13)
ALS 8 VAPB AD AAO: adult > juvenile; Onset: limb; None SMA, motor neuropathy, autonomic dysfunction
(20q13.3) Progression: slow; LMN dominant
ALS 9 ANG AD AAO: adult > juvenile; Onset: limb, bulbar; Yes PBP, PD
(14q11.2) Progression: N/A; UMN + LMN
ALS 10 TARDBP AD; AR AAO: adult; Onset: limb, bulbar; Yes PSP, FTD with Parkinsonism, PD, chorea
(1p36.22) Progression: variable; UMN + LMN
ALS 11 FIG4 AD AAO: adult; Onset: bulbar > limb; None CMT4J, HSP, PLS, Yunis–Varon syndrome, epilepsy
with polymicrogyria
(6q21) Progression: variable; UMN + LMN > UMN
dominant
ALS 12 OPTN AD; AR AAO: adult; Onset: bulbar, limb; Yes POAG, Parkinsonism, aphasia
(10p13) Progression: slow; UMN + LMN
ALS 13 ATXN2 AD AAO: adult > juvenile; Onset: UL, LL; None SCA2, Parkinsonism
(12q24) Progression: variable; UMN + LMN
ALS 14 VCP AD AAO: adult > juvenile; Onset: limb > bulbar; Yes IBMPFD
(9p13) Progression: variable; UMN + LMN
ALS 15 UBQLN2 XD AAO: adult > juvenile; Onset: limb, bulbar; Yes PLS
(Xp11.21) Progression: variable; UMN + LMN > UMN
dominant
ALS 16 SIGMAR1 AD AAO: juvenile; Onset: LL > UL; Rare motor neuropathy
(9p13.3) Progression: N/A; UMN + LMN
ALS 17 CHMP2B AD AAO: adult; Onset: bulbar, limb; Yes PMA; Parkinsonism
(3p12.1) Progression: N/A; UMN + LMN > LMN dominant
ALS 18 PFN1 AD AAO: adult; Onset: limb; None N/A
(17p13.2) Progression: N/A; UMN + LMN
ALS 19 ERBB4 AD AAO: adult; Onset: UL, bulbar; None N/A
(2q33.3-q34) Progression: slow; UMN + LMN
ALS 20 hnRNPA1 AD AAO: adult; Onset: N/A; Yes multisystem proteinopathy
(12q13.1) Progression: N/A; UMN + LMN > LMN dominant
ALS 21 MATR3 AD AAO: adult; Onset: bulbar, limb; Yes distal myopathy
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[14]. Another novel p.T137A mutation identified in two
unrelated Italian families, however, causes a very slow
progression of ALS [26, 27].
ALS2: Alsin
Mutations in ALS2 are responsible for autosomal re-
cessive, early-onset forms of upper motor neuron dis-
eases, such as infantile ascending hereditary spastic
paraplegia (IAHSP) and juvenile primary lateral scler-
osis (PLS) [28, 29]. To date, more than 50 patients
with early onset (~1 year) of the disease have been re-
ported to harbor Alsin mutations [18]. In the typical
adult onset ALS, Alsin gene is rarely mutated [30].
Recently, a novel splice-site mutation (c.3512 + 1G > A)
in Alsin was identified in a consanguineous JALS
family with early onset anarthria and generalized
dystonia [31].
ALS4: senataxin (SETX)
ALS4 is a rare autosomal dominant form of juvenile-onset
ALS due to mutations in SETX [32]. It is characterized by
slowly evolving distal muscle weakness and atrophy, pyram-
idal signs, and sparing of bulbar and respiratory muscles
[33]. In some cases, normal lifespan or atypical features are
also described [34, 35]. A patient with SETX p.R2136C
mutation presented with coexistence of ALS and inflamma-
tory radiculoneuropathy [36]. We previously reported a
missense mutation p.T1118I in a sporadic Chinese ALS pa-
tient who developed bulbar symptoms 3 years after the on-
set, and respiratory failure 2 years later [37]. In addition,
recessive SETX mutations are reported to cause ataxia and
oculomotor apraxia type 2 (AOA2) [38, 39].
ALS5: spatacsin (SPG11)
SPG11 mutations were recently identified in several
juvenile-onset ALS cases, with autosomal recessive in-
heritance and AAO ranging from 7 to 23 years [18, 40].
Generally, the SPG11-associated ALS showed a slow
progression and in some cases apparent UMN involve-
ment [41]. In addition to ALS phenotype, mutations in
SPG11 also cause hereditary spastic paraplegia (HSP)
with thin corpus callosum [42].
ALS6: FUS
Mutations in FUS gene have emerged as the second
most common cause of ALS, accounting for about 3 ~
5 % FALS and ~1 % SALS [43, 44]. Up to now, more
than 60 mutations in FUS have been identified in ALS
cases (http://www.hgmd.org, accessed in March, 2015).
Among these mutations, the majority are clustered in
exon 15 which encode the C-terminus of the protein,
and the most common one is p.R521C [15]. The inherit-
ance is autosomal dominant aside from an autosomal
recessive p.H517Q mutation and several de novo muta-
tions [44].
The phenotypes associated with FUS mutations in-
clude adult-onset ALS, JALS, ALS-FTD, and rarely pure
FTD [45]. Although most patients carrying FUS muta-
tions exhibit a classical ALS phenotype without cognitive
impairment, the clinical course of these ALS cases are
diverse, even among carriers of the same mutations.
Compared to SOD1 patients, FUS-related ALS have an
earlier AAO, more frequent bulbar disease, and a more
rapid progression [46]. Some FUS mutations are also ob-
served in patients with juvenile-onset ALS with AAO
younger than 25 years [47, 48]. Atypical features such as
ALS with mental retardation, ALS with parkinsonism
and dementia [46], and essential tremor were seen in
some patients with FUS mutations [49].
ALS8: vesicle associated membrane protein B (VAPB)
VAPB mutation was firstly described in several Brazilian
families with motor neuron degeneration of various pat-
terns: late-onset spinal muscular atrophy, atypical ALS,
or typical ALS [50]. Subsequently, five other point muta-
tions and a small deletion were described. Overall,VAPB
mutations are extremely rare in FALS. The phenotype-
genotype correlation remains largely undetermined so
far.
ALS9: angiogenin (ANG)
The role of ANG mutations in ALS remains ambiguous.
Approximate 30 ANG mutations have been reported in
ALS, but only the p.K17II mutation is shown to co-
segregate with the disease [51]. Mutations in ANG ac-
count for a small fraction of ALS cases. A few FALS
cases are identified to have concomitant ANG mutations
Table 1 Different subtypes of familial ALS and their genotype–phenotype correlations (Continued)
(5q31.3) Progression: slow; UMN + LMN > LMN dominant
ALS-FTD C9ORF72 AD AAO: adult; Onset: bulbar, limb; Yes Parkinsonism, cerebellar ataxia
(9p21.2) Progression: rapid > slow; UMN + LMN
Abbreviations: AAO age at onset, AD autosomal dominant, ALS amyotrophic lateral sclerosis, AOA2 ataxia and oculomotor apraxia type 2, AR autosomal recessive,
BFA benign focal amyotrophy, CMT4J Charcot-Marie-Tooth disease, FTD frontotemporal dementia, HSP hereditary spastic paraplegia, IAHSP infantile-onset ascending
hereditary spastic paralysis, IBMPFD inclusion body myopathy with Paget’s disease and frontotemporal dementia, LL lower limb, LMN lower motor neuron, N/A not
available, PBP progressive bulbar palsy, PD Parkinson’s disease, PLS primary lateral sclerosis, PMA progressive muscular atrophy, POAG primary open angle glaucoma,
PSP progressive supranuclear palsy, SCA2 spinocerebellar ataxia 2, UL upper limb, UMN upper motor neuron; UN unknown, XD X-linked dominant
Li and Wu Translational Neurodegeneration  (2016) 5:3 Page 4 of 10
with FUS [52] or SOD1 [53] mutations. In addition,
some ANG mutations are detected in healthy controls
[54]. A subset of ANG mutation carriers showed cogni-
tive impairment suggestive of FTD [55], or Parkinson’s
disease (PD) [56].
ALS10: TARDBP
Mutations in TARDBP encoding TDP-43 account for
4 % of FALS cases and ~1 % of SALS [57, 58]. More
than 50 mutations have been identified so far (http://
www.hgmd.org, accessed in March, 2015), mostly clus-
tered in the C-terminal region encoded by exon 6 of
TARDBP. Mutations in TARDBP are predominantly mis-
sense with an autosomal dominant inheritance. Al-
though TARDBP mutations are detected in ALS cases
worldwide, some regional diversity does exist. For in-
stance, the p.A382T mutation has been found in 28.7 %
of all ALS cases in Sardinia [59].
Patients with TARDBP mutations usually exhibit a typ-
ical ALS phenotype, with limb or bulbar onset, variable
disease course, and no overt dementia [60]. It is reported
that the TARDBP–linked ALS has a trend for earlier
AAO, more upper limb onset, and a longer duration,
compared to SALS patients [52, 61]. However, we previ-
ously reported a TARDBP p.S292N mutation in a FALS
case who developed dysarthria, dysphagia, and atrophy
of lingual muscle at the age of 64 years [62]. The pro-
gression of ALS in this case seemed to be rapid. Other
phenotypes associated with TARDBP mutations include
FTD [63], ALS-FTD [64], ALS with extrapyramidal signs
[65], FTD with parkinsonism [66], and PD [67].
ALS11: factor induced gene 4 (FIG4)
FIG4 was previously implicated in Charcot-Marie-Tooth
disease type 4J (CMT4J) [68]. Later, FIG4 mutations
were found in autosomal dominant FALS and SALS
cases [69]. However, ALS was a rare phenotype of FIG4
gene. The other phenotypes associated with FIG4 muta-
tions include PLS [69], Yunis–Varon syndrome [70], and
familial epilepsy with polymicrogyria [71].
ALS12: optineurin (OPTN)
Previously identified as the cause of primary open angle
glaucoma (POAG) [72], mutations in OPTN have been
found in both FALS and SALS cases in either a domin-
ant or recessive manner [73]. Although OPTN muta-
tions are relatively common in Japan ALS cases [73, 74],
they are rare in Caucasian patients [75, 76]. The
OPTN-related ALS showed relatively slow progression
and long duration before respiratory dysfunction [73].
In addition to ALS phenotype, some patients with
OPTN mutations present with extrapyramidal symp-
toms, aphasia, or FTD [77, 78].
ALS13: Ataxin-2 (ATXN2)
Long (more than 33) CAG repeat expansion in ATXN2
gene has been identified as a cause of spinocerebellar
ataxia type 2 (SCA2) [79]. Recent studies demonstrated
that intermediate expansion (27 ~ 33 repeats) of ATXN2
was a significant risk factor for ALS [80–82]. However,
whether the clinical features of ALS can be affected by
ATXN2 intermediate repeats is still controversial, be-
cause no correlation between ATXN2 repeat length and
AAO or survival was observed [83]. A few case reports
have described motor neuron degeneration in SCA2
families, raising the possibility that motor neuron in-
volvement is part of SCA2 [84, 85].
ALS14: Valosin-containing protein (VCP)
The gene of VCP is known to be mutated in inclusion
body myopathy with Paget disease of bone and fronto-
temporal dementia (IBMPFD) [86]. Recently, mutations
in VCP were identified in patients with FALS or SALS
[87]. Actually, VCP mutations are not a major cause of
ALS. Although more than 38 mutations in VCP have
been discovered (http://www.hgmd.org, accessed in
March, 2015), only a few of them are responsible for
ALS. The phenotype of patients with VCP mutations
shows intra-familial variations from IBMPFD to FALS
[88], or from ALS to FTD or ALS-FTD [87].
ALS15: ubiquilin 2 (UBQLN2)
Mutations in UBQLN2 were recently identified in X-
linked dominant FALS [89]. However, UBQLN2 mutations
are not a frequent cause of ALS [90]. In the affected cases,
incomplete penetrance has been noted in females [89].
The predominant phenotype associated with UBQLN2
mutations is ALS, although several patients have con-
comitant symptoms of FTD [10]. The AAO has been re-
ported to be significantly younger in males than in
females, presumably because males are hemizygous but
females are heterozygous for the mutation [89].
ALS16: sigma non-opioid intracellular receptor 1
(SIGMAR1)
SIGMAR1 mutations were recently identified in families
affected with juvenile ALS [91] or ALS with dementia
[92]. However, these findings have not been replicated
by other groups, suggesting that SIGMAR1 is a rare
causative gene of ALS. Recently a splice-site mutation
(c.151 + 1G > T) in SIGMAR1 was reported to cause
autosomal recessive distal hereditary motor neuropathy
in a consanguineous Chinese family [93].
ALS17: chromatin modifying protein 2B (CHMP2B)
Mutations in the CHMP2B gene were initially identified
in patients with FTD [94] and then identified in
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patients with ALS [95, 96]. Since only several ALS
cases with CHMP2B mutations were reported, there
was no characteristic ALS clinical subtype associated
with these patients. In addition, CHMP2B mutation
(p.R69Q) was also identified in progressive muscular at-
rophy (PMA) [96].
ALS18: profilin 1 (PFN1)
Missense mutations in PFN1 are firstly reported in two
large ALS families and 7 FALS patients [97]. Later,
screenings of sizeable ALS and FTD cohorts from di-
verse populations demonstrated that PFN1 mutations
are a rare cause of ALS [98–100]. The reported cases
with PFN1 mutations seem to present classical ALS with
limb onset and no evidence of FTD [97, 99, 101].
ALS19: erb-b2 receptor tyrosine kinase 4 (ERBB4)
Recently, ERBB4 was identified a causative gene of
FALS19, which was characterized by typical, slowly pro-
gressive ALS and a lack of obvious cognitive dysfunction
[102]. However, this finding has not been replicated by
other groups. The genotype-phenotype correlations are
thus not determined.
ALS20: heterogeneous nuclear ribonucleoprotein A1
(hnRNPA1)
Mutations in hnRNPA1 gene were recently identified in
patients presenting with ALS and/or multisystem protei-
nopathy (MSP) [103]. However, subsequent studies failed
to identify hnRNPA1 mutations in patients with ALS,
FTD, or MSP [103–105]. The associations of ALS with
hnRNPA1 mutations are still controversial.
ALS21: matrin-3 (MATR3)
Several mutations in MATR3 were recently reported to
cause ALS [106]. Later, a heterozygous MATR3 p.A72T
mutation was identified in a sporadic ALS patient with
bulbar onset [107]. In another study, 2 splicing variants
and a missense mutation were identified in 3 ALS cases
with AAO ranging from 58 to 79 years, and bulbar onset
in 2 cases [108].
ALS-FTD: C9ORF72
In 2011, two independent groups reported that the
massive GGGGCC hexanucleotide repeat expansion in
the non-coding regions of C9ORF72 gene caused
chromosome 9p-linked ALS and FTD [109, 110]. Cur-
rently, C9ORF72 repeat expansions have become the
most frequently genetic cause of FALS and familial FTD,
accounting for about 40 and 25 % of the cases, respect-
ively [13]. In families with ALS-FTD, the frequency
reaches to 50–72 % [19]. Notwithstanding, the muta-
tions seem to be geographically clustered, accounting for
one third of FALS cases in Europe and North America,
but a small percentage in Asian populations. Haplotype
analysis indicates that a common European founder ap-
pears to be responsible for all cases [111].
The C9ORF72 repeat expansions are associated with
various phenotypes, including typical ALS, PMA, PLS,
ALS-FTD, and pure FTD [44]. In patients with
C9ORF72 mutations, bulbar onset and cognitive impair-
ment seems to be more frequent, and median survival is
relatively lower than in patients carrying TARDBP or
SOD1 mutations [19]. However, there is no association
between the repeat length and disease phenotype or
AAO in C9ORF72 mutation carriers [112]. In addition,
the C9ORF72 expansions also underlie a small portion
of other neurological diseases, such as Alzheimer’s dis-
ease (AD) [113], Huntington’s disease (HD) [114], and
PD [115].
Other genes implicated in ALS
Several other genes are also implicated in ALS. DCTN1
mutations were first identified in a family affected with
LMN disease [116] and soon identified in several ALS
families [117, 118]. Subsequently, a cluster of DCTN1
mutations were identified in pedigrees with Perry syn-
drome [119], PD [120] or progressive supranuclear par-
alysis (PSP) [121], suggestive of phenotypic variability of
DCTN1 mutations. Mutations in SQSTM1 were initially
identified as a cause of Paget disease of bone (PDB)
[122]. Recently, SQSTM1 mutations were identified in
ALS [123, 124] as well as FTD [125]. It is speculated that
SQSTM1 mutations are mainly associated with late-
onset SALS, because the number of early-onset patients
with SQSTM1 mutations is much less than that of late-
onset patients with SQSTM1 mutations [126].
In addition, mutations in several other genes such as
DAO, UNC13A, NEFH, PRPH, TAF15, and ELP3, have
been reported as rare causes of ALS. For some genes,
there are no additional reports about the mutations as a
cause of ALS since the initial publications. Therefore,
the evidence supporting a causative role of ALS is not
fully convincing.
Implication of the genotype-phenotype
correlations
There is no a standard procedure to test the causative
mutation in cases with ALS. Many factors should be
considered, such as AAO, clinical features, progression,
FTD involvement, inheritance manner, and even ethni-
city. In this review, we summarized the possible
genotype-phenotype correlations of ALS with the aim of
providing some clue to improve the clinical decision.
Here, we provided a flow diagram of genetic screening
strategy in cases diagnosed with ALS (Fig. 1). AAO is an
importance factor for the genetic investigations and can
be divided into juvenile onset and adult onset. Juvenile
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onset is usually present in ALS1, ALS2, ALS4, ALS5,
ALS6, ALS8, ALS9, ALS13, ALS15, and ALS16. For
these cases with juvenile onset and UMN dominant
symptoms, Alsin, SPG11, SIGMAR1, or UBQLN2 might
be a causative gene. In contrast, FUS, VAPB, SOD1, and
SETX should be considered in cases with juvenile onset
and LMN dominant phenotype. For these cases with ju-
venile onset and FTD symptoms, ANG, UBQLN2, and
SIGMAR1 can be investigated. In addition, SPG11 and
FUS can be sequenced in cases who also present mental
retardation, while SOD1, Alsin, SETX, ATXN2 can be
considered in those cases with coexistence of cerebellar
ataxia.
In cases with adult-onset ALS, many genes should be
considered. Although the majority exhibit typical ALS
features with both UMN and LMN symptoms, a fraction
of cases present either UMN dominant symptoms or
LMN dominant symptoms. SPG11, FIG4, UBQLN2 may
be mutated in cases with UMN dominant symptoms. In
these cases with LMN dominant symptoms, mutations
in SOD1, SETX, FUS, VAPB, VCP, CHMP2B, hnRNPA1,
or MATR3 might be identified. Presence of FTD hints
possible mutations in ANG, TARDBP, OPTN, VCP,
UBQLN2, CHMP2B, hnRNPA1, MATR3, or C9ORF72.
Motor neuropathy involvement might occur in cases
with mutations in SETX, VAPB, or FIG4. Complications
of ataxia may be seen in cases with SOD1 or ATXN2
mutations.
Inheritance pattern also provides critical information
as to the potential involvement of one or other specific
genes in ALS. However, the diverse clinical features be-
tween intra-familial cases or a deceased parent at a
young age may results in the appearance of “lack of fa-
milial history” in some cases. The presentation of ALS
or FTD in first-degree relatives and the co-occurrence of
ALS with FTD in some patients with ALS supported a
positive family history. In addition, ethnic background
should be considered when determining which genes are
most likely. For example, C9ORF72 has been regarded as
the most common cause of ALS in Caucasians, but very
rare in Asian population.
Conclusions
Here, we outline the genotype-phenotype correlations of
ALS. We hope this review is helpful for detecting the
causative mutation in cases with ALS. Although a num-
ber of genes have been reported, many ALS cases still
do not carry any mutation in the aforementioned genes.
Other more genes might be identified as causative genes
of ALS in the future.
Abbreviations
AAO: age at onset; AD: Alzheimer’s disease; ALS: amyotrophic lateral sclerosis;
ANG: angiogenin; AOA2: oculomotor apraxia type 2; ATXN2: ataxin-2;
C9ORF72: chromosome 9 open reading frame 72; CMT4J: Charcot-Marie-
Tooth disease; DCTN1: dynactin; ERBB4: erb-b2 receptor tyrosine kinase 4;
FALS: familial amyotrophic lateral sclerosis; FIG4: factor induced gene 4;
FTD: frontal temporal dementia; FUS: fused in sarcoma; HD: Huntington’s
disease; hnRNPA1: heterogeneous nuclear ribonucleoprotein A1;
HSP: hereditary spastic paraplegia; IAHSP: infantile-onset ascending
hereditary spastic paralysis; IBMPFD: inclusion body myopathy with Paget
disease of bone and frontotemporal dementia; JALS: juvenile amyotrophic
lateral sclerosis; LMN: lower motor neuron; MATR3: matrin-3;
MSP: multisystem proteinopathy; OPTN: optineurin; PD: Parkinson’s disease;
PDB: Paget disease of bone; PFN1: profilin 1; PLS: juvenile primary lateral
sclerosis; PMA: progressive muscular atrophy; PSP: progressive supranuclear
paralysis; SALS: sporadic amyotrophic lateral sclerosis; SCA: spinocerebellar
ataxia; SETX: senataxin; SIGMAR1: sigma non-opioid intracellular receptor 1;
SOD1: superoxide dismutase 1; SPG11: spatacsin; SQSTM1: sequestosome 1;
TARDBP: TAR DNA-binding protein; UBQLN2: ubiquilin 2; UMN: upper motor
neuron; VAPB: vesicle associated membrane protein B.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
L-HF drafted and W-ZY critically revised the manuscript. Both authors read
and approved the final manuscript.
Acknowledgements
This work was supported by grants from the National Natural Science
Foundation to Zhi-Ying Wu (81125009, Beijing).
Received: 1 July 2015 Accepted: 27 January 2016
References
1. Logroscino G, Traynor BJ, Hardiman O, Chio A, Mitchell D, Swingler RJ, et al.
Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg
Psychiatry. 2010;81:385–90.
2. Sathasivam S. Motor neurone disease: clinical features, diagnosis, diagnostic
pitfalls and prognostic markers. Singapore Med J. 2010;51:367–72. quiz 73.
3. Finsterer J, Burgunder JM. Recent progress in the genetics of motor neuron
disease. Eur J Med Genet. 2014;57:103–12.
4. Forbes RB, Colville S, Swingler RJ. The epidemiology of amyotrophic lateral
sclerosis (ALS/MND) in people aged 80 or over. Age Ageing. 2004;33:131–4.
5. Gouveia LO, de Carvalho M. Young-onset sporadic amyotrophic lateral
sclerosis: a distinct nosological entity? Amyotroph Lateral Scler.
2007;8:323–7.
6. McCombe PA, Henderson RD. Effects of gender in amyotrophic lateral
sclerosis. Gend Med. 2010;7:557–70.
7. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al.
Amyotrophic lateral sclerosis. Lancet. 2011;377:942–55.
Fig. 1 A flow diagram of genetic screening strategy in cases
diagnosed with ALS
Li and Wu Translational Neurodegeneration  (2016) 5:3 Page 7 of 10
8. Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE.
Prevalence and patterns of cognitive impairment in sporadic ALS.
Neurology. 2005;65:586–90.
9. Burrell JR, Kiernan MC, Vucic S, Hodges JR. Motor neuron dysfunction in
frontotemporal dementia. Brain. 2011;134:2582–94.
10. Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis
genetics. Nat Neurosci. 2014;17:17–23.
11. Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes,
environment and time. Nat Rev Neurol. 2013;9:617–28.
12. Deng HX, Hentati A, Tainer JA, Iqbal Z, Cayabyab A, Hung WY, et al.
Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide
dismutase. Science. 1993;261:1047–51.
13. Baumer D, Talbot K, Turner MR. Advances in motor neurone disease. J R Soc
Med. 2014;107:14–21.
14. Tortelli R, Conforti FL, Cortese R, D’Errico E, Distaso E, Mazzei R, et al.
Amyotrophic lateral sclerosis: a new missense mutation in the SOD1 gene.
Neurobiol Aging. 2013;1709(34):e3–5.
15. Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis:
what do we really know? Nature reviews. Neurology. 2011;7:603–15.
16. Jonsson PA, Backstrand A, Andersen PM, Jacobsson J, Parton M, Shaw C,
et al. CuZn-superoxide dismutase in D90A heterozygotes from recessive
and dominant ALS pedigrees. Neurobiol Dis. 2002;10:327–33.
17. Saeed M, Yang Y, Deng HX, Hung WY, Siddique N, Dellefave L, et al. Age
and founder effect of SOD1 A4V mutation causing ALS. Neurology.
2009;72:1634–9.
18. Yamashita S, Ando Y. Genotype-phenotype relationship in hereditary
amyotrophic lateral sclerosis. Transl Neurodegener. 2015;4:13.
19. Sabatelli M, Conte A, Zollino M. Clinical and genetic heterogeneity of
amyotrophic lateral sclerosis. Clin Genet. 2013;83:408–16.
20. Andersen PM, Forsgren L, Binzer M, Nilsson P, Ala-Hurula V, Keranen ML,
et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis
associated with homozygosity for Asp90Ala CuZn-superoxide dismutase
mutation. A clinical and genealogical study of 36 patients. Brain.
1996;119(Pt 4):1153–72.
21. Parton MJ, Broom W, Andersen PM, Al-Chalabi A, Nigel Leigh P, Powell JF,
et al. D90A-SOD1 mediated amyotrophic lateral sclerosis: a single founder
for all cases with evidence for a Cis-acting disease modifier in the recessive
haplotype. Hum Mutat. 2002;20:473.
22. Robberecht W, Aguirre T, Van den Bosch L, Tilkin P, Cassiman JJ, Matthijs G.
D90A heterozygosity in the SOD1 gene is associated with familial and
apparently sporadic amyotrophic lateral sclerosis. Neurology. 1996;47:1336–9.
23. Juneja T, Pericak-Vance MA, Laing NG, Dave S, Siddique T. Prognosis in
familial amyotrophic lateral sclerosis: progression and survival in patients
with glu100gly and ala4val mutations in Cu, Zn superoxide dismutase.
Neurology. 1997;48:55–7.
24. Aksoy H, Dean G, Elian M, Deng HX, Deng G, Juneja T, et al. A4T mutation
in the SOD1 gene causing familial amyotrophic lateral sclerosis.
Neuroepidemiology. 2003;22:235–8.
25. Niu YF, Xiong HL, Wu JJ, Chen Y, Qiao K, Wu ZY. [Screening of mutations in
SOD1 gene and analysis of genotype-phenotype correlation in Chinese
patients with amyotrophic lateral sclerosis]. Yi chuan = Hereditas /
Zhongguo yi chuan xue hui bian ji. 2011;33:720–4.
26. Origone P, Caponnetto C, Verdiani S, Mantero V, Cichero E, Fossa P, et al.
T137A variant is a pathogenetic SOD1 mutation associated with a slowly
progressive ALS phenotype. Amyotroph Lateral Scler. 2012;13:398–9.
27. Visani M, de Biase D, Bartolomei I, Plasmati R, Morandi L, Cenacchi G, et al. A
novel T137A SOD1 mutation in an Italian family with two subjects affected
by amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011;12:385–8.
28. Hadano S, Hand CK, Osuga H, Yanagisawa Y, Otomo A, Devon RS, et al. A
gene encoding a putative GTPase regulator is mutated in familial
amyotrophic lateral sclerosis 2. Nat Genet. 2001;29:166–73.
29. Eymard-Pierre E, Lesca G, Dollet S, Santorelli FM, di Capua M, Bertini E, et al.
Infantile-onset ascending hereditary spastic paralysis is associated with
mutations in the alsin gene. Am J Hum Genet. 2002;71:518–27.
30. Hand CK, Devon RS, Gros-Louis F, Rochefort D, Khoris J, Meininger V, et al.
Mutation screening of the ALS2 gene in sporadic and familial amyotrophic
lateral sclerosis. Arch Neurol. 2003;60:1768–71.
31. Siddiqi S, Foo JN, Vu A, Azim S, Silver DL, Mansoor A, et al. A novel splice-
site mutation in ALS2 establishes the diagnosis of juvenile amyotrophic
lateral sclerosis in a family with early onset anarthria and generalized
dystonias. PLoS One. 2014;9:e113258.
32. Chen YZ, Bennett CL, Huynh HM, Blair IP, Puls I, Irobi J, et al. DNA/RNA
helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis
(ALS4). Am J Hum Genet. 2004;74:1128–35.
33. Hirano M, Quinzii CM, Mitsumoto H, Hays AP, Roberts JK, Richard P, et al.
Senataxin mutations and amyotrophic lateral sclerosis. Amyotroph Lateral
Scler. 2011;12:223–7.
34. Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis:
insights from genetics. Nat Rev Neurosci. 2006;7:710–23.
35. Rabin BA, Griffin JW, Crain BJ, Scavina M, Chance PF, Cornblath DR.
Autosomal dominant juvenile amyotrophic lateral sclerosis. Brain.
1999;122(Pt 8):1539–50.
36. Saiga T, Tateishi T, Torii T, Kawamura N, Nagara Y, Shigeto H, et al.
Inflammatory radiculoneuropathy in an ALS4 patient with a novel SETX
mutation. J Neurol Neurosurg Psychiatry. 2012;83:763–4.
37. Zhao ZH, Chen WZ, Wu ZY, Wang N, Zhao GX, Chen WJ, et al. A novel
mutation in the senataxin gene identified in a Chinese patient with
sporadic amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10:118–22.
38. Chen YZ, Hashemi SH, Anderson SK, Huang Y, Moreira MC, Lynch DR, et al.
Senataxin, the yeast Sen1p orthologue: characterization of a unique protein
in which recessive mutations cause ataxia and dominant mutations cause
motor neuron disease. Neurobiol Dis. 2006;23:97–108.
39. Moreira MC, Klur S, Watanabe M, Nemeth AH, Le Ber I, Moniz JC, et al.
Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular
apraxia 2. Nat Genet. 2004;36:225–7.
40. Orlacchio A, Babalini C, Borreca A, Patrono C, Massa R, Basaran S, et al.
SPATACSIN mutations cause autosomal recessive juvenile amyotrophic
lateral sclerosis. Brain. 2010;133:591–8.
41. Iguchi Y, Katsuno M, Ikenaka K, Ishigaki S, Sobue G. Amyotrophic lateral
sclerosis: an update on recent genetic insights. J Neurol. 2013;260:2917–27.
42. Paisan-Ruiz C, Dogu O, Yilmaz A, Houlden H, Singleton A. SPG11 mutations
are common in familial cases of complicated hereditary spastic paraplegia.
Neurology. 2008;70:1384–9.
43. Polymenidou M, Lagier-Tourenne C, Hutt KR, Bennett CF, Cleveland DW,
Yeo GW. Misregulated RNA processing in amyotrophic lateral sclerosis. Brain
Res. 2012;1462:3–15.
44. Boylan K. Familial Amyotrophic Lateral Sclerosis. Neurol Clin. 2015;33:807–30.
45. Deng H, Gao K, Jankovic J. The role of FUS gene variants in
neurodegenerative diseases. Nat Rev Neurol. 2014;10:337–48.
46. Yan J, Deng HX, Siddique N, Fecto F, Chen W, Yang Y, et al. Frameshift and
novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/
dementia. Neurology. 2010;75:807–14.
47. Baumer D, Hilton D, Paine SM, Turner MR, Lowe J, Talbot K, et al. Juvenile
ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations.
Neurology. 2010;75:611–8.
48. Munoz DG. FUS mutations in sporadic juvenile ALS: another step toward
understanding ALS pathogenesis. Neurology. 2010;75:584–5.
49. Merner ND, Girard SL, Catoire H, Bourassa CV, Belzil VV, Riviere JB, et al.
Exome sequencing identifies FUS mutations as a cause of essential tremor.
Am J Hum Genet. 2012;91:313–9.
50. Nishimura AL, Mitne-Neto M, Silva HC, Richieri-Costa A, Middleton S, Cascio
D, et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset
spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet.
2004;75:822–31.
51. van Es MA, Diekstra FP, Veldink JH, Baas F, Bourque PR, Schelhaas HJ, et al.
A case of ALS-FTD in a large FALS pedigree with a K17I ANG mutation.
Neurology. 2009;72:287–8.
52. Millecamps S, Salachas F, Cazeneuve C, Gordon P, Bricka B, Camuzat A, et al.
SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic
lateral sclerosis: genotype-phenotype correlations. J Med Genet. 2010;47:
554–60.
53. Luigetti M, Lattante S, Zollino M, Conte A, Marangi G, Del Grande A, et al.
SOD1 G93D sporadic amyotrophic lateral sclerosis (SALS) patient with rapid
progression and concomitant novel ANG variant. Neurobiol Aging.
2011;1924(32):e15–8.
54. Gellera C, Colombrita C, Ticozzi N, Castellotti B, Bragato C, Ratti A, et al.
Identification of new ANG gene mutations in a large cohort of Italian
patients with amyotrophic lateral sclerosis. Neurogenetics. 2008;9:33–40.
55. Seilhean D, Cazeneuve C, Thuries V, Russaouen O, Millecamps S, Salachas F,
et al. Accumulation of TDP-43 and alpha-actin in an amyotrophic lateral
sclerosis patient with the K17I ANG mutation. Acta Neuropathol.
2009;118:561–73.
Li and Wu Translational Neurodegeneration  (2016) 5:3 Page 8 of 10
56. van Es MA, Schelhaas HJ, van Vught PW, Ticozzi N, Andersen PM, Groen EJ,
et al. Angiogenin variants in Parkinson disease and amyotrophic lateral
sclerosis. Ann Neurol. 2011;70:964–73.
57. Millecamps S, Boillee S, Le Ber I, Seilhean D, Teyssou E, Giraudeau M, et al.
Phenotype difference between ALS patients with expanded repeats in
C9ORF72 and patients with mutations in other ALS-related genes. J Med
Genet. 2012;49:258–63.
58. Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic
lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010;9:995–1007.
59. Chio A, Borghero G, Pugliatti M, Ticca A, Calvo A, Moglia C, et al. Large
proportion of amyotrophic lateral sclerosis cases in Sardinia due to a single
founder mutation of the TARDBP gene. Arch Neurol. 2011;68:594–8.
60. Kirby J, Goodall EF, Smith W, Highley JR, Masanzu R, Hartley JA, et al. Broad
clinical phenotypes associated with TAR-DNA binding protein (TARDBP)
mutations in amyotrophic lateral sclerosis. Neurogenetics. 2010;11:217–25.
61. Corcia P, Valdmanis P, Millecamps S, Lionnet C, Blasco H, Mouzat K, et al.
Phenotype and genotype analysis in amyotrophic lateral sclerosis with
TARDBP gene mutations. Neurology. 2012;78:1519–26.
62. Xiong HL, Wang JY, Sun YM, Wu JJ, Chen Y, Qiao K, et al. Association
between novel TARDBP mutations and Chinese patients with amyotrophic
lateral sclerosis. BMC Med Genet. 2010;11:8.
63. Gitcho MA, Bigio EH, Mishra M, Johnson N, Weintraub S, Mesulam M, et al.
TARDBP 3′-UTR variant in autopsy-confirmed frontotemporal lobar
degeneration with TDP-43 proteinopathy. Acta Neuropathol. 2009;118:633–45.
64. Benajiba L, Le Ber I, Camuzat A, Lacoste M, Thomas-Anterion C, Couratier P,
et al. TARDBP mutations in motoneuron disease with frontotemporal lobar
degeneration. Ann Neurol. 2009;65:470–3.
65. Origone P, Caponnetto C, Bandettini Di Poggio M, Ghiglione E, Bellone E,
Ferrandes G, et al. Enlarging clinical spectrum of FALS with TARDBP gene
mutations: S393L variant in an Italian family showing phenotypic variability
and relevance for genetic counselling. Amyotroph Lateral Scler.
2010;11:223–7.
66. Quadri M, Cossu G, Saddi V, Simons EJ, Murgia D, Melis M, et al. Broadening
the phenotype of TARDBP mutations: the TARDBP Ala382Thr mutation and
Parkinson’s disease in Sardinia. Neurogenetics. 2011;12:203–9.
67. Rayaprolu S, Fujioka S, Traynor S, Soto-Ortolaza AI, Petrucelli L, Dickson DW,
et al. TARDBP mutations in Parkinson’s disease. Parkinsonism Relat Disord.
2013;19:312–5.
68. Chow CY, Zhang Y, Dowling JJ, Jin N, Adamska M, Shiga K, et al. Mutation
of FIG4 causes neurodegeneration in the pale tremor mouse and patients
with CMT4J. Nature. 2007;448:68–72.
69. Chow CY, Landers JE, Bergren SK, Sapp PC, Grant AE, Jones JM, et al.
Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients
with ALS. Am J Hum Genet. 2009;84:85–8.
70. Campeau PM, Lenk GM, Lu JT, Bae Y, Burrage L, Turnpenny P, et al.
Yunis-Varon syndrome is caused by mutations in FIG4, encoding a
phosphoinositide phosphatase. Am J Hum Genet. 2013;92:781–91.
71. Baulac S, Lenk GM, Dufresnois B, Ouled Amar Bencheikh B, Couarch P,
Renard J, et al. Role of the phosphoinositide phosphatase FIG4 gene in
familial epilepsy with polymicrogyria. Neurology. 2014;82:1068–75.
72. Rezaie T, Child A, Hitchings R, Brice G, Miller L, Coca-Prados M, et al. Adult-
onset primary open-angle glaucoma caused by mutations in optineurin.
Science. 2002;295:1077–9.
73. Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, et al. Mutations
of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465:223–6.
74. Iida A, Hosono N, Sano M, Kamei T, Oshima S, Tokuda T, et al. Novel
deletion mutations of OPTN in amyotrophic lateral sclerosis in Japanese.
Neurobiol Aging. 2012;1843(33):e19–24.
75. Johnson L, Miller JW, Gkazi AS, Vance C, Topp SD, Newhouse SJ, et al.
Screening for OPTN mutations in a cohort of British amyotrophic lateral
sclerosis patients. Neurobiol Aging. 2012;33:2948. e15-7.
76. Millecamps S, Boillee S, Chabrol E, Camu W, Cazeneuve C, Salachas F, et al.
Screening of OPTN in French familial amyotrophic lateral sclerosis.
Neurobiol Aging. 2011;32:557. e11-3.
77. Kamada M, Izumi Y, Ayaki T, Nakamura M, Kagawa S, Kudo E, et al.
Clinicopathologic features of autosomal recessive amyotrophic lateral
sclerosis associated with optineurin mutation. Neuropathology. 2014;34:64–70.
78. Weishaupt JH, Waibel S, Birve A, Volk AE, Mayer B, Meyer T, et al. A novel
optineurin truncating mutation and three glaucoma-associated missense
variants in patients with familial amyotrophic lateral sclerosis in Germany.
Neurobiol Aging. 2013;34:1516. e9-15.
79. Imbert G, Saudou F, Yvert G, Devys D, Trottier Y, Garnier JM, et al. Cloning
of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity
to expanded CAG/glutamine repeats. Nat Genet. 1996;14:285–91.
80. Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, et al.
Ataxin-2 intermediate-length polyglutamine expansions are associated with
increased risk for ALS. Nature. 2010;466:1069–75.
81. Liu X, Lu M, Tang L, Zhang N, Chui D, Fan D. ATXN2 CAG repeat expansions
increase the risk for Chinese patients with amyotrophic lateral sclerosis.
Neurobiol Aging. 2013;34:2236. e5-8.
82. Lu HP, Gan SR, Chen S, Li HF, Liu ZJ, Ni W, et al. Intermediate-length
polyglutamine in ATXN2 is a possible risk factor among Eastern Chinese
patients with amyotrophic lateral sclerosis. Neurobiol Aging. 2014;36:1603.
83. Van Damme P, Veldink JH, van Blitterswijk M, Corveleyn A, van Vught PW,
Thijs V, et al. Expanded ATXN2 CAG repeat size in ALS identifies genetic
overlap between ALS and SCA2. Neurology. 2011;76:2066–72.
84. Infante J, Berciano J, Volpini V, Corral J, Polo JM, Pascual J, et al.
Spinocerebellar ataxia type 2 with Levodopa-responsive parkinsonism
culminating in motor neuron disease. Mov Disord. 2004;19:848–52.
85. Nanetti L, Fancellu R, Tomasello C, Gellera C, Pareyson D, Mariotti C. Rare
association of motor neuron disease and spinocerebellar ataxia type 2
(SCA2): a new case and review of the literature. J Neurol. 2009;256:1926–8.
86. Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, et al.
Inclusion body myopathy associated with Paget disease of bone and
frontotemporal dementia is caused by mutant valosin-containing protein.
Nat Genet. 2004;36:377–81.
87. Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM,
Trojanowski JQ, et al. Exome sequencing reveals VCP mutations as a cause
of familial ALS. Neuron. 2010;68:857–64.
88. Gonzalez-Perez P, Cirulli ET, Drory VE, Dabby R, Nisipeanu P, Carasso RL,
et al. Novel mutation in VCP gene causes atypical amyotrophic lateral
sclerosis. Neurology. 2012;79:2201–8.
89. Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N, et al.
Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset
ALS and ALS/dementia. Nature. 2011;477:211–5.
90. Millecamps S, Corcia P, Cazeneuve C, Boillee S, Seilhean D, Danel-Brunaud V,
et al. Mutations in UBQLN2 are rare in French amyotrophic lateral sclerosis.
Neurobiol Aging. 2012;33:839. e1-3.
91. Al-Saif A, Al-Mohanna F, Bohlega S. A mutation in sigma-1 receptor causes
juvenile amyotrophic lateral sclerosis. Ann Neurol. 2011;70:913–9.
92. Belzil VV, Daoud H, Camu W, Strong MJ, Dion PA, Rouleau GA. Genetic
analysis of SIGMAR1 as a cause of familial ALS with dementia. Eur J Hum
Genet. 2013;21:237–9.
93. Li X, Hu Z, Liu L, Xie Y, Zhan Y, Zi X, et al. A SIGMAR1 splice-site
mutation causes distal hereditary motor neuropathy. Neurology.
2015;84:2430–7.
94. Skibinski G, Parkinson NJ, Brown JM, Chakrabarti L, Lloyd SL, Hummerich H,
et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in
frontotemporal dementia. Nat Genet. 2005;37:806–8.
95. Cox LE, Ferraiuolo L, Goodall EF, Heath PR, Higginbottom A, Mortiboys H,
et al. Mutations in CHMP2B in lower motor neuron predominant
amyotrophic lateral sclerosis (ALS). PLoS One. 2010;5:e9872.
96. van Blitterswijk M, Vlam L, van Es MA, van der Pol WL, Hennekam EA,
Dooijes D, et al. Genetic overlap between apparently sporadic motor
neuron diseases. PLoS One. 2012;7:e48983.
97. Wu CH, Fallini C, Ticozzi N, Keagle PJ, Sapp PC, Piotrowska K, et al.
Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis.
Nature. 2012;488:499–503.
98. Daoud H, Dobrzeniecka S, Camu W, Meininger V, Dupre N, Dion PA, et al.
Mutation analysis of PFN1 in familial amyotrophic lateral sclerosis patients.
Neurobiol Aging. 2013;34:1311. e1-2.
99. Ingre C, Landers JE, Rizik N, Volk AE, Akimoto C, Birve A, et al. A novel
phosphorylation site mutation in profilin 1 revealed in a large screen of US,
Nordic, and German amyotrophic lateral sclerosis/frontotemporal dementia
cohorts. Neurobiol Aging. 2013;1708(34):e1–6.
100. Lattante S, Le Ber I, Camuzat A, Brice A, Kabashi E. Mutations in the PFN1
gene are not a common cause in patients with amyotrophic lateral sclerosis
and frontotemporal lobar degeneration in France. Neurobiol Aging.
2013;1709(34):e1–2.
101. Smith BN, Vance C, Scotter EL, Troakes C, Wong CH, Topp S, et al. Novel
mutations support a role for Profilin 1 in the pathogenesis of ALS.
Neurobiol Aging. 2015;1602(36):e17–27.
Li and Wu Translational Neurodegeneration  (2016) 5:3 Page 9 of 10
102. Takahashi Y, Fukuda Y, Yoshimura J, Toyoda A, Kurppa K, Moritoyo H,
et al. ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway
cause amyotrophic lateral sclerosis type 19. Am J Hum Genet.
2013;93:900–5.
103. Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, Diaz Z, et al.
Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause
multisystem proteinopathy and ALS. Nature. 2013;495:467–73.
104. Seelen M, Visser AE, Overste DJ, Kim HJ, Palud A, Wong TH, et al. No
mutations in hnRNPA1 and hnRNPA2B1 in Dutch patients with amyotrophic
lateral sclerosis, frontotemporal dementia, and inclusion body myopathy.
Neurobiol Aging. 2014;35:1956. e9-56 e11.
105. Le Ber I, Van Bortel I, Nicolas G, Bouya-Ahmed K, Camuzat A, Wallon D, et al.
hnRNPA2B1 and hnRNPA1 mutations are rare in patients with “multisystem
proteinopathy” and frontotemporal lobar degeneration phenotypes.
Neurobiol Aging. 2014;35:934. e5-6.
106. Johnson JO, Pioro EP, Boehringer A, Chia R, Feit H, Renton AE, et al.
Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis.
Nat Neurosci. 2014;17:664–6.
107. Lin KP, Tsai PC, Liao YC, Chen WT, Tsai CP, Soong BW, et al. Mutational
analysis of MATR3 in Taiwanese patients with amyotrophic lateral sclerosis.
Neurobiol Aging. 2005;2015(36):e1–4.
108. Leblond CS, Gan-Or Z, Spiegelman D, Laurent SB, Szuto A, Hodgkinson A,
et al. Replication study of MATR3 in familial and sporadic amyotrophic
lateral sclerosis. Neurobiol Aging. 2015;37:209.
109. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M,
Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in
noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.
Neuron. 2011;72:245–56.
110. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR,
et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of
chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257–68.
111. Smith BN, Newhouse S, Shatunov A, Vance C, Topp S, Johnson L, et al. The
C9ORF72 expansion mutation is a common cause of ALS+/−FTD in Europe
and has a single founder. Eur J Hum Genet. 2013;21:102–8.
112. Rutherford NJ, Heckman MG, Dejesus-Hernandez M, Baker MC, Soto-
Ortolaza AI, Rayaprolu S, et al. Length of normal alleles of C9ORF72
GGGGCC repeat do not influence disease phenotype. Neurobiol Aging.
2012;33:2950. e5-7.
113. Majounie E, Abramzon Y, Renton AE, Perry R, Bassett SS, Pletnikova O, et al.
Repeat expansion in C9ORF72 in Alzheimer’s disease. N Engl J Med.
2012;366:283–4.
114. Hensman Moss DJ, Poulter M, Beck J, Hehir J, Polke JM, Campbell T, et al.
C9orf72 expansions are the most common genetic cause of Huntington
disease phenocopies. Neurology. 2014;82:292–9.
115. Lesage S, Le Ber I, Condroyer C, Broussolle E, Gabelle A, Thobois S, et al.
C9orf72 repeat expansions are a rare genetic cause of parkinsonism. Brain.
2013;136:385–91.
116. Puls I, Jonnakuty C, LaMonte BH, Holzbaur EL, Tokito M, Mann E, et al.
Mutant dynactin in motor neuron disease. Nat Genet. 2003;33:455–6.
117. Liu ZJ, Li HF, Tan GH, Tao QQ, Ni W, Cheng XW, et al. Identify mutation in
amyotrophic lateral sclerosis cases using HaloPlex target enrichment system.
Neurobiol Aging. 2014;35:2881. e11-5.
118. Munch C, Rosenbohm A, Sperfeld AD, Uttner I, Reske S, Krause BJ, et al.
Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS
and FTD. Ann Neurol. 2005;58:777–80.
119. Farrer MJ, Hulihan MM, Kachergus JM, Dachsel JC, Stoessl AJ, Grantier LL,
et al. DCTN1 mutations in Perry syndrome. Nat Genet. 2009;41:163–5.
120. Araki E, Tsuboi Y, Daechsel J, Milnerwood A, Vilarino-Guell C, Fujii N, et al. A
novel DCTN1 mutation with late-onset parkinsonism and frontotemporal
atrophy. Mov Disord. 2014;29:1201–4.
121. Caroppo P, Le Ber I, Clot F, Rivaud-Pechoux S, Camuzat A, De Septenville A,
et al. DCTN1 mutation analysis in families with progressive supranuclear
palsy-like phenotypes. JAMA Neurol. 2014;71:208–15.
122. Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutation of the
gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone.
Am J Hum Genet. 2002;70:1582–8.
123. Fecto F, Yan J, Vemula SP, Liu E, Yang Y, Chen W, et al. SQSTM1 mutations
in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol.
2011;68:1440–6.
124. Hirano M, Nakamura Y, Saigoh K, Sakamoto H, Ueno S, Isono C, et al.
Mutations in the gene encoding p62 in Japanese patients with
amyotrophic lateral sclerosis. Neurology. 2013;80:458–63.
125. Rubino E, Rainero I, Chio A, Rogaeva E, Galimberti D, Fenoglio P, et al.
SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic
lateral sclerosis. Neurology. 2012;79:1556–62.
126. Chen Y, Zheng ZZ, Chen X, Huang R, Yang Y, Yuan L, et al. SQSTM1
mutations in Han Chinese populations with sporadic amyotrophic lateral
sclerosis. Neurobiol Aging. 2014;35:726. e7-9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Li and Wu Translational Neurodegeneration  (2016) 5:3 Page 10 of 10
